Princeton Biomeditech Corp — Federal Contractor Profile
PRINCETON BIOMEDITECH CORP Secures $57.5 Million in Federal Contracts
Contractor Overview
Total Contract Value: $57,456,000 ($57.5M)
Total Awards: 2
Company Profile
PRINCETON BIOMEDITECH CORP is a federal contractor with a significant presence in government spending, having secured a total of $57.5 million in contracts. The company has not won any recent contracts, and its sole-source rate is 0, indicating that all contracts were competitive. Given the lack of recent contracts, it is unclear what specific areas the company is currently focusing on. The company's top agency clients are not specified, which could indicate a diversified client base or a lack of significant reliance on any single agency. The average contract size of $2,87,28,000 suggests that the company is involved in large-scale projects, which could be indicative of its core capabilities and the nature of its government business. The absence of recent contracts and the lack of detailed information on specific projects and performance history makes it challenging to assess the company's track record and strategic direction. Given the company's size and the nature of its contracts, it is likely a niche player in the biotechnology and medical technology sectors, providing specialized services to the federal government. The company's contract patterns reveal a focus on competitive bidding, which is a positive sign for ensuring fair and transparent processes. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history raise concerns about the company's current business strategy and its ability to secure future contracts.
Specializations
- Biotechnology
- Medical Technology
- Pharmaceuticals
- Biomedical Research
- Clinical Trials
- Regenerative Medicine
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: N/A
Growth Trajectory: N/A
Sole Source Rate: 0%
Recompete Rate: N/A
Competitive Position
PRINCETON BIOMEDITECH CORP appears to be a niche player in the biotechnology and medical technology sectors, focusing on specialized services that are in high demand by the federal government. The company's reliance on competitive bidding suggests that it is well-positioned to compete with other contractors in its field. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history make it difficult to assess its market position relative to competitors.
Value to Taxpayers
Given the company's focus on specialized services and the competitive nature of its contracts, PRINCETON BIOMEDITECH CORP likely provides good value for taxpayer money. The average contract size of $28,728,000 suggests that the company is involved in large-scale projects, which could be indicative of its core capabilities and the nature of its government business. However, without detailed information on specific projects and performance history, it is challenging to make a definitive assessment of the company's value to taxpayers.
Agency Relationships
The lack of specified top agency clients makes it difficult to assess the company's relationship with specific government agencies. However, the absence of significant reliance on any single agency could indicate a diversified client base, which could be a positive sign for reducing dependency risks. The lack of recent contracts and the absence of detailed information on specific projects and performance history make it challenging to assess the company's current level of engagement with government agencies.
Red Flags
- Lack of recent contracts: The absence of recent contracts could indicate that the company is facing challenges in securing new business, which could be a concern for government agencies relying on its services.
- No detailed performance history: The lack of detailed information on specific projects and performance history makes it challenging to assess the company's track record and its ability to deliver on its commitments.
- No specified top agency clients: The absence of specified top agency clients could indicate a lack of significant reliance on any single agency, which could be a concern for government agencies relying on its services.
Green Flags
- 100% competitive win rate: The company's reliance on competitive bidding suggests that it is well-positioned to compete with other contractors in its field.
- No sole-source awards: The absence of sole-source awards indicates that the company is not relying on non-competitive processes to secure contracts.
- Large average contract size: The average contract size of $28,728,000 suggests that the company is involved in large-scale projects, which could be indicative of its core capabilities and the nature of its government business.
Key Contracts
PRINCETON BIOMEDITECH CORP has secured a total of $57.5 million in contracts, with an average contract size of $2,87,28,000. While the company has not won any recent contracts, its track record of securing large-scale projects suggests that it has the capability to deliver on its commitments. The company's focus on specialized services in the biotechnology and medical technology sectors is likely a key factor in its ability to secure contracts. However, the lack of detailed information on specific projects and performance history makes it challenging to assess the company's track record and its ability to deliver on its commitments. The company's contract patterns reveal a focus on competitive bidding, which is a positive sign for ensuring fair and transparent processes. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history raise concerns about the company's current business strategy and its ability to secure future contracts.
Frequently Asked Questions
What does PRINCETON BIOMEDITECH CORP do for the federal government?
PRINCETON BIOMEDITECH CORP specializes in biotechnology and medical technology, providing specialized services to the federal government. The company's core capabilities include biomedical research, pharmaceuticals, regenerative medicine, and clinical trials. Its services are likely focused on supporting government agencies in areas such as public health, defense, and scientific research.
How much taxpayer money does PRINCETON BIOMEDITECH CORP receive?
PRINCETON BIOMEDITECH CORP has secured a total of $57.5 million in contracts, with an average contract size of $2,87,28,000. The company has not won any recent contracts, which could indicate that it is facing challenges in securing new business. However, the company's track record of securing large-scale projects suggests that it has the capability to deliver on its commitments.
Is PRINCETON BIOMEDITECH CORP good value for taxpayer money?
Given the company's focus on specialized services and the competitive nature of its contracts, PRINCETON BIOMEDITECH CORP likely provides good value for taxpayer money. The average contract size of $28,728,000 suggests that the company is involved in large-scale projects, which could be indicative of its core capabilities and the nature of its government business. However, without detailed information on specific projects and performance history, it is challenging to make a definitive assessment of the company's value to taxpayers.
How does PRINCETON BIOMEDITECH CORP win its contracts?
PRINCETON BIOMEDITECH CORP relies on competitive bidding to secure its contracts, which is a positive sign for ensuring fair and transparent processes. The company's focus on specialized services in the biotechnology and medical technology sectors is likely a key factor in its ability to secure contracts. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history make it challenging to assess the company's competitive history and its ability to secure future contracts.
What agencies use PRINCETON BIOMEDITECH CORP most?
The lack of specified top agency clients makes it difficult to assess the company's relationship with specific government agencies. However, the absence of significant reliance on any single agency could indicate a diversified client base, which could be a positive sign for reducing dependency risks. The lack of recent contracts and the absence of detailed information on specific projects and performance history make it challenging to assess the company's current level of engagement with government agencies.
What are the risks of relying on PRINCETON BIOMEDITECH CORP?
The absence of recent contracts and the lack of detailed information on specific projects and performance history raise concerns about the company's current business strategy and its ability to secure future contracts. The company's focus on specialized services in the biotechnology and medical technology sectors is likely a key factor in its ability to secure contracts, but the lack of recent contracts and the absence of detailed information on specific projects and performance history make it challenging to assess the company's track record and its ability to deliver on its commitments. The company's contract patterns reveal a focus on competitive bidding, which is a positive sign for ensuring fair and transparent processes. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history raise concerns about the company's current business strategy and its ability to secure future contracts.
How does PRINCETON BIOMEDITECH CORP compare to similar contractors?
PRINCETON BIOMEDITECH CORP appears to be a niche player in the biotechnology and medical technology sectors, focusing on specialized services that are in high demand by the federal government. The company's reliance on competitive bidding suggests that it is well-positioned to compete with other contractors in its field. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history make it difficult to assess its market position relative to competitors. The company's contract patterns reveal a focus on competitive bidding, which is a positive sign for ensuring fair and transparent processes. However, the lack of recent contracts and the absence of detailed information on specific projects and performance history raise concerns about the company's current business strategy and its ability to secure future contracts.
Recent Federal Contracts
Princeton Biomeditech Corp has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards Princeton Biomeditech $28.7M for OTC COVID-19 Tests | Department of Health and Human Services | $28.7M | N/A |